Glenza, containing Enzalutamide as the active ingredient, is an oral medication used to treat certain types of prostate cancer. It is classified as an androgen receptor inhibitor and works by blocking the effects of androgens (male hormones) that promote the growth of cancer cells.

Uses:

1. Metastatic castration-resistant prostate cancer (mCRPC).
2. Non-metastatic castration-resistant prostate cancer (nmCRPC).
3. Metastatic hormone-sensitive prostate cancer (mHSPC).

Enzalutamide binds to androgen receptors on prostate cancer cells, preventing androgens like testosterone from activating these receptors. This inhibits the growth and survival of prostate cancer cells.

Dosage and Administration:

• Typical dosage: 160 mg daily, taken as 4 capsules of 40 mg each.
• Taken orally with or without food.
• Dosage adjustments may be required for specific conditions or side effects.

Side Effects:
Common side effects:

• Fatigue.
• Hot flashes.
• Weakness.
• Back pain.
• Hypertension (high blood pressure).

Serious side effects:

• Seizures.
• Risk of falls.
• Heart issues like arrhythmias.

Precautions:

• Regular monitoring of blood pressure and liver function is recommended.
• Avoid in patients with a history of seizures or severe neurological conditions.
• Not recommended for women, especially during pregnancy or breastfeeding.
• Use with caution in elderly patients.

Drug Interactions:

• Avoid concurrent use with strong CYP2C8 and CYP3A4 inhibitors or inducers.
• Can interact with warfarin, antiepileptics, and other medications.

Storage Instructions:

• Store at room temperature (20–25°C).
• Keep away from moisture and direct sunlight.